Latest News

Market capUnder $100B
SectorsAll
Filter by sector
Friday, October 16, 2026· 7957 stock ideas· 217 writers·
17,301 views· 8,017 clicks

From X

@kevin__mak 3 clicks

Kevin Mak on X

$ABVX Interesting data coming from S&P Markit* (daily short interest based on institutional lending data). Looks like someone established a large position over the past 10 days or so, about 2mm shares or $200M. Given people generally don't like to have single name short exposure over 1-2% of their book (often people size shorts as like ~50 bps), this would be part of a really big book or a really big basket trade. Given the current ABVX-specific situation, it feels weird to be directly betting on the stock falling further from these levels, without any known catalysts around. My best guess is this is part of a "short France" basket trade. But I also can't find any other items of the basket with large changes in short interest to corroborate. Retail Fintwit crowding (correlation with other popular bio names) is likely having an effect as well. Plus rates. Plus biotech degrossing. What I ruled out was a world where this could/would be frontrunning ahead of a possible liquidation (There's a fund with a large ABVX position that took a huge loss on LQDA), but the timing on that is off. In fact pretty much the whole short position was established prior to LQDA crashing. My observation is that the list of items above, plausibly causing weakness in the stock, largely has nothing to do with A) Does the drug work, B) Will the drug sell well. That's what I like about situations like this. ABVX is a large position for us, we've spent a long time recently double/triple checking our fundamental views on the stock and still strongly believe that their key drug, Obefazimod, will be successful even without an acquisition. Hope to have a detailed write-up about that at some point. *I find Markit data to be the most reliable among 3rd party short data, but there are still data anomalies for various reasons. Disclosure: Creek Drive and its affiliated funds holds a long position in ABVX. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.

Free Recaps of the best new stock ideas, delivered every morning.

Is The Market Turning The Page?

CoreWeave’s debt and equity price action is framed as a wake-up call for investors amid a broader market discussion.

PesoRama: Research Flash

PesoRama will reach 54 JOi Dollar Plus stores by November after raising C$28.4 million, funding more than 50 additional Mexican store…

Modine Deep Dive

Modine, soon Modexus Solutions, has a $4 billion hyperscaler cooling contract but must ramp factory output and restore margins as data…

AppLovin Deep Dive

AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens…

Constellation: Stars Aligning?

Constellation Brands trades near $127 at roughly 11x next-twelve-month EV/EBIT, with recent business results offsetting concerns over…

BLND · long

Blend Labs INC

Blend Labs (BLND) is presented as a long investment idea, with prior VIC writeups cited for business background.

Have a source we’re missing? Send your pick

Recent recaps

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

X accounts we follow

Every account on this site, hand-picked.

88 accounts

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick